Published in Arch Intern Med on October 01, 1966
Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry (2007) 4.37
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) (2006) 4.23
Opiate versus psychostimulant addiction: the differences do matter. Nat Rev Neurosci (2011) 2.05
The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect (2002) 1.99
Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep (1998) 1.98
Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol (2010) 1.93
Mu opioids and their receptors: evolution of a concept. Pharmacol Rev (2013) 1.66
Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med (2006) 1.56
Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health (1998) 1.54
A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse (2009) 1.49
Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag (2009) 1.44
The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment. Ann Gen Psychiatry (2016) 1.40
Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health (1995) 1.40
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest (2012) 1.26
Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis (2012) 1.25
Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis (2010) 1.23
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend (2006) 1.19
Evidence-based practices for substance use disorders. Psychiatr Clin North Am (2003) 1.05
Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats. Psychopharmacology (Berl) (2009) 1.05
Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. Brain Res (2009) 1.01
Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opin Pharmacol (2009) 0.99
Centres for treatment of drug addiction. Advantages of special centres. Br Med J (1967) 0.99
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs (2012) 0.99
Bidirectional translational research: Progress in understanding addictive diseases. Neuropharmacology (2008) 0.99
Effect of fenfluramine on reinstatement of food seeking in female and male rats: implications for the predictive validity of the reinstatement model. Psychopharmacology (Berl) (2011) 0.98
Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure. Int J Neuropsychopharmacol (2015) 0.96
Evaluation of a low-threshold/high-tolerance methadone maintenance treatment clinic in saint john, new brunswick, Canada: one year retention rate and illicit drug use. J Addict (2012) 0.94
Distinct profiles of anxiety and dysphoria during spontaneous withdrawal from acute morphine exposure. Neuropsychopharmacology (2009) 0.92
One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel. J Addict Dis (2008) 0.91
Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society. Behav Pharmacol (2010) 0.87
Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal. Neuropsychopharmacology (2012) 0.87
Developing a vaccine against multiple psychoactive targets: a case study of heroin. CNS Neurol Disord Drug Targets (2011) 0.87
Episodic withdrawal promotes psychomotor sensitization to morphine. Neuropsychopharmacology (2010) 0.87
It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol (2014) 0.86
Contingency management interventions: effects on treatment outcome during methadone detoxification. J Appl Behav Anal (1984) 0.86
Methadone plasma level: sustained by a reservoir of drug in tissue. Proc Natl Acad Sci U S A (1973) 0.83
Overview and historical perspective of four papers presented on research related to the endogenous opioid system. Drug Alcohol Depend (2010) 0.82
Continued drug use during methadone treatment in China: a retrospective analysis of 19,026 service users. J Subst Abuse Treat (2013) 0.82
Effects of 7-day continuous D-amphetamine, methylphenidate, and cocaine treatment on choice between methamphetamine and food in male rhesus monkeys. Drug Alcohol Depend (2015) 0.81
Functions of arginine vasopressin and its receptors: importance of human molecular genetics studies in bidirectional translational research. Biol Psychiatry (2011) 0.80
The use of propoxyphene napsylate in the treatment of heroin and methadone addiction. West J Med (1974) 0.80
Methadone. Can Med Assoc J (1973) 0.80
The effects of buprenorphine on fentanyl withdrawal in rats. Psychopharmacology (Berl) (2007) 0.79
Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications. Neuropsychopharmacology (2010) 0.79
Fecal impaction following methadone ingestion simulating acute intestinal obstruction,. Ann Surg (1975) 0.78
Clonazepam as agonist substitution treatment for benzodiazepine dependence: a case report. Case Rep Psychiatry (2013) 0.78
Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics. Int J Environ Res Public Health (2011) 0.77
Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet (2015) 0.76
Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder. Ann N Y Acad Sci (2016) 0.76
Hospital care at Second Avenue and East 17th Street, New York City, 1894-1984. Bull N Y Acad Med (1984) 0.75
Group-based strategies for stress reduction in methadone maintenance treatment: what do patients want? J Addict Med (2011) 0.75
Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Ann N Y Acad Sci (2011) 0.75
Steady-state methadone effect on generalized arousal in male and female mice. Behav Neurosci (2008) 0.75
Measures against drug addiction. Br Med J (1967) 0.75
Burden and nutritional deficiencies in opiate addiction- systematic review article. Iran J Public Health (2014) 0.75
Opioid substitution: improving cost-efficiency. Bull World Health Organ (2013) 0.75
Current approaches to the treatment of narcotic addiction. J Natl Med Assoc (1969) 0.75
Selected bibliography on narcotic addiction treatment, 1960-1966. Reports of treatment programs. Am J Public Health Nations Health (1967) 0.75
New treatments for heroin addiction. Br Med J (1967) 0.75
To Be Free and Normal: Addiction, Governance, and the Therapeutics of Buprenorphine. Med Anthropol Q (2015) 0.75
HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA (1989) 6.68
THE PROPERTIES OF T ANTIGENS EXTRACTED FROM GROUP A HEMOLYTIC STREPTOCOCCI. J Exp Med (1946) 5.62
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
AN INACTIVE PRECURSOR OF STREPTOCOCCAL PROTEINASE. J Exp Med (1947) 3.19
Successful treatment of 750 criminal addicts. JAMA (1968) 2.36
Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav (2008) 2.00
Methadone treatment of randomly selected criminal addicts. N Engl J Med (1969) 1.97
Heroin addiction--a metabolic disease. Arch Intern Med (1967) 1.77
Rifampin-induced methadone withdrawal. N Engl J Med (1976) 1.70
Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med (1966) 1.69
Methadone treatment and the acquired immunodeficiency syndrome epidemic. JAMA (1989) 1.60
ESTIMATION OF BLOOD VOLUME FROM CHANGE IN BLOOD SPECIFIC GRAVITY FOLLOWING A PLASMA INFUSION. J Clin Invest (1946) 1.59
Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry (2004) 1.56
Toward an analogue of alcoholism in mice: scale factors in the model. Proc Natl Acad Sci U S A (1984) 1.55
Predictable individual differences in the initiation of cocaine self-administration by rats under extended-access conditions are dose-dependent. Psychopharmacology (Berl) (2001) 1.53
The present status of methadone blockade treatment. Am J Psychiatry (1967) 1.47
In vitro studies of the effect of methadone on natural killer cell activity. Isr J Med Sci (1990) 1.46
Rehabilitation of the street addict. Arch Environ Health (1967) 1.37
Biochemistry of addiction. Annu Rev Biochem (1970) 1.36
Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther (1985) 1.35
Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav (2009) 1.32
'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res Mol Brain Res (1993) 1.32
Methadone maintenance patients in general medical practice. A preliminary report. JAMA (1988) 1.28
Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport (1994) 1.28
Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol (1989) 1.27
Long-term outcome of patients treated with methadone maintenance. Ann N Y Acad Sci (1978) 1.26
Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry (2008) 1.25
Long-term methadone maintenance therapy: effects on liver function. Ann Intern Med (1972) 1.23
Medical safety and side effects of methadone in tolerant individuals. JAMA (1973) 1.17
Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther (1989) 1.16
Methadone and immune function. Am J Med (1992) 1.15
Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res (2001) 1.15
Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet (1983) 1.15
Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther (1996) 1.14
Evaluation of narcotics treatment programs. Am J Public Health Nations Health (1967) 1.12
Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol (2000) 1.12
Chronic cocaine alters brain mu opioid receptors. Brain Res (1992) 1.11
Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther (1981) 1.10
Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32. J Neurosci (2006) 1.09
Addictive behaviour and the art of medicine. Subst Alcohol Actions Misuse (1983) 1.09
Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology (2001) 1.08
Detection of narcotic drugs, tranquilizers, amphetamines, and barbiturates in urine. JAMA (1966) 1.06
Time course of the development of behavioral sensitization and dopamine receptor up-regulation during binge cocaine administration. J Pharmacol Exp Ther (1994) 1.06
Neuroendocrine alterations in a high-dose, extended-access rat self-administration model of escalating cocaine use. Psychoneuroendocrinology (2003) 1.05
The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res (2001) 1.05
Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin Pharmacol Ther (2010) 1.05
Estrous cycle differences in cocaine-induced stereotypic and locomotor behaviors in Fischer rats. Behav Brain Res (1999) 1.05
Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res (1997) 1.04
Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol (1998) 1.04
Methadone disposition during the perinatal period in humans. Pharmacol Biochem Behav (1979) 1.04
Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J Pharmacol Exp Ther (2000) 1.04
Nicotine addiction: insights from recent animal studies. Psychopharmacology (Berl) (2002) 1.03
Chronic administration of a cocaine "binge" alters basal extracellular levels in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther (1995) 1.02
ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides (1984) 1.02
Effects of "binge" pattern cocaine on stereotypy and locomotor activity in C57BL/6J and 129/J mice. Pharmacol Biochem Behav (1998) 1.02
Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. J Infect Dis (1988) 1.01
Portal hypertension with bleeding vaginal varices. Ann Intern Med (1967) 1.01
Methadone maintenance treatment for 25,000 heroin addicts. JAMA (1971) 1.01
Why does a sucrose choice reduce the consumption of alcohol in C57BL/6J mice? Life Sci (1987) 1.01
Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction. Am J Med Genet (2000) 1.00
Toward an analogue of alcoholism in mice: criteria for recognition of pharmacologically motivated drinking. Proc Natl Acad Sci U S A (1985) 1.00
Methadone-maintained former heroin addicts, including those who are anti-HIV-1 seropositive, comply with and respond to hepatitis B vaccination. Addiction (1999) 0.99
Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat (2010) 0.99
An improved technique for monitoring the drinking behavior of mice. Physiol Behav (1983) 0.99
Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res (1998) 0.99
Psychiatric comorbidity in methadone maintained patients. J Addict Dis (1998) 0.99
Detoxification of sick addicts in prison. JAMA (1972) 0.98
Idiopathic cholestasis of pregnancy. The response to challenge with the synthetic estrogen, ethinyl estradiol. N Engl J Med (1967) 0.98
Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: a case of naloxone-induced withdrawal. Metabolism (1997) 0.97
Arousal of ethanol-intoxicated comatose patients with naloxone. Alcohol Clin Exp Res (1982) 0.96
Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Brain Res Mol Brain Res (1995) 0.96
Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther (2000) 0.96
GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther (2001) 0.96
Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse (1993) 0.96
Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. N Y State J Med (1973) 0.96
Narcotic addiction, physical dependence and relapse. N Engl J Med (1972) 0.96
Subject-regulated dosing alters morphine self-administration behavior and morphine-stimulated [35S]GTPgammaS binding. Synapse (2003) 0.96
Localization of d- and l-methadone after intraventricular injection into rat brains. J Pharmacol Exp Ther (1970) 0.95
Medical complications in methadone patients. Ann N Y Acad Sci (1978) 0.95
Methadone maintenance. Outcome after termination. N Y State J Med (1977) 0.94
Reduced hypothalamic POMC and anterior pituitary CRF1 receptor mRNA levels after acute, but not chronic, daily "binge" intragastric alcohol administration. Alcohol Clin Exp Res (2000) 0.94
Quantitation of preproenkephalin mRNA levels in brain regions from male Fischer rats following chronic cocaine treatment using a recently developed solution hybridization assay. Brain Res Mol Brain Res (1992) 0.94
Narcotic blockade--a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians (1966) 0.93
Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of mother maintained on methadone. Am J Drug Alcohol Abuse (1974) 0.93
Metyrapone-induced withdrawal symptoms. Br J Addict (1990) 0.93
Amygdalar vasopressin mRNA increases in acute cocaine withdrawal: evidence for opioid receptor modulation. Neuroscience (2005) 0.93
Effects of binge pattern cocaine administration on dopamine D1 and D2 receptors in the rat brain: an in vivo study using positron emission tomography. J Neurosci (1996) 0.92
The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend (1993) 0.92
Serial determination of plasma ethanol concentrations in mice. Physiol Behav (1983) 0.92
Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther (1992) 0.92
Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin. Neuroscience (2008) 0.91
Regulation of kappa opioid receptor mRNA in the rat brain by "binge' pattern cocaine administration and correlation with preprodynorphin mRNA. Brain Res Mol Brain Res (1996) 0.91